<DOC>
	<DOCNO>NCT02068040</DOCNO>
	<brief_summary>The major goal proposal characterize ability epicatechin component dark chocolate improve 1. structural functional feature skeletal muscle ( SkM ) 2. exercise capacity ( assessed VO2 max ) 3. parameter diastolic heart function ( assessed echocardiography ) We propose 3 month treatment epicatechin ( CocoaViaÂ® capsule ) lead significant improvement exercise capacity diastolic function .</brief_summary>
	<brief_title>Effects Epicatechin Functional Capacity , Skeletal Muscle Structure Diastolic Function Patients With Heart Failure With Preserved Ejection Fraction ( HFPEF )</brief_title>
	<detailed_description>Patient Inclusion/Exclusion Criteria : 1 . New York Heart Association Class II/III HF preserve ejection fraction ( EF ) &gt; 50 % . 2 . Nonsmokers 3 . Subject take Coumadin , Xarelto , Prasugrel Pradaxa . Patients Plavix drug elute stent exclude . 4 . Ages 40-65 . We exclude woman child bear potential</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Medically Diagnosed Heart Failure Ejection Fraction &gt; 55 % BMI 2732 No Significant HbA1C fluctuation past 6 month Smoking quit smoking le 1 year prior enrollment Substance Abuse Taking Coudmadin Pradaxa</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>preserve ejection fraction &gt; 55 %</keyword>
</DOC>